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Abstract
We assessed the risks of bleeding, acute kidney injury (AKI), and kidney failure asso-
ciated with the prescription of antithrombotic agents (oral anticoagulants and/or anti-
platelet agents) in patients with moderate- to- advanced chronic kidney disease (CKD). 
CKD- REIN is a prospective cohort of 3022 nephrology outpatients with CKD stages 
2– 5 at baseline. We used cause- specific Cox proportional hazard models to estimate 
hazard ratios (HRs) for bleeding (identified through hospitalizations), AKI, and kid-
ney failure. Prescriptions of oral antithrombotics were treated as time- dependent vari-
ables. At baseline, 339 (11%) patients (65% men; 69 [60– 76] years) were prescribed 
oral anticoagulants only, 1095 (36%) antiplatelets only, and 101 (3%) both type of 
oral antithrombotics. Over a median (interquartile range [IQR]) follow- up period of 
3.0 (IQR, 2.8– 3.1) years, 152 patients experienced a bleeding event, 414 patients 
experienced an episode of AKI, and 270 experienced kidney failure. The adjusted 
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INTRODUCTION
Patients with chronic kidney disease (CKD) have an elevated 
risk of cardiovascular morbidity and mortality.1– 6 CKD 
is associated with a high prevalence of both atheromatous 
cardiovascular vascular disease (CVD; such as coronary ar-
tery disease and stroke) and nonatheromatous CVD (such 
as heart failure and atrial fibrillation).7 These comorbidities 
result in the frequent prescription of cardiovascular drugs.8 
In fact, CKD is an important risk factor for thrombosis inde-
pendently of comorbidities, like diabetes, hypertension, and 
high blood cholesterol.9 Specific risk factors for thrombosis 
have been identified in patients with CKD, such as uremic 
toxins (notably indoxyl sulfate and indole- 3- acetic acid).10– 12 
The pathogenesis of bleeding in CKD is considered to be 
multifactorial. The main abnormalities concern primary 
hemostasis and platelet- platelet or platelet- vessel- wall inter-
actions.13 A recent study of a mouse model of kidney failure 
showed that moderate CKD was associated with a hyperco-
agulation state, whereas severe CKD was associated with a 
risk of bleeding.14 This seemingly incompatible combination 
in CKD— “more thrombosis, more bleeding”— constitutes a 
huge challenge in nephrology research and complicates treat-
ment with antithrombotic drugs (such as oral anticoagulants 
and antiplatelet agents) in these patients.15
Moreover, patients with CKD (and especially those 
with advanced CKD) are under- represented in random-
ized controlled clinical trials of oral anticoagulants and 
antiplatelet agents. Although antithrombotic drugs have a 
well- established risk/benefit ratio in the general popula-
tion, conflicting results have been published for patients 
with CKD,16– 22 in whom major bleeding is the prime safety 
2012 to 2017, Sanofi- Genzyme from 
2012 to 2015, and Vifor Fresenius and 
AstraZeneca since 2018. INSERM 
Transfert set up and has managed this 
partnership since 2011. A specific project 
on drug optimization in patients with 
CKD was funded by the French National 
Agency for Medicines and Health 
Products Safety (ANSM).
HRs (95% confidence interval [95% CI]) for bleeding associated with prescriptions of 
antiplatelets only, oral anticoagulants only, and antiplatelet + oral anticoagulant were, 
respectively, 0.74 (95% CI, 0.46– 1.19), 2.38 (95% CI, 1.45– 3.89), and 3.96 (95% CI, 
2.20– 7.12). An increased risk of AKI risk was associated with the prescription of oral 
anticoagulants (adjusted HR, 1.90, 95% CI, 1.47– 2.45) but not the prescription of 
antiplatelets (HR, 1.24, 95% CI, 0.98– 1.56). Kidney failure was not associated with 
the prescription of oral antithrombotics of any type. This study confirms the high risk 
of AKI associated with oral anticoagulants prescription in patients with CKD and also 
highlights the potential aggravating effect of combining vitamin K antagonist (VKA) 
and antiplatelets on the risk of bleeding.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Patients with chronic kidney disease (CKD) are prone to develop serious adverse 
drug reactions due to antithrombotic agents. Randomized clinical trial rarely include 
patients with moderate to severe CKD.
WHAT QUESTION DID THIS STUDY ADDRESS?
This study assesses the impact of (i) oral antithrombotics and (ii) the interactions be-
tween oral anticoagulants and antiplatelet agents on the occurrence of serious adverse 
events, such as bleeding episodes requiring an emergency department visit or hospital 
admission, acute kidney injury (AKI), and CKD progression.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
The risk of bleeding associated to oral anticoagulant was high in patients with CKD 
with estimated glomerular filtration rate (eGFR) less than 30  ml/min/1.73  m2 and 
was even higher when patients take concomitantly oral anticoagulant and antiplatelet 
therapy. Oral anticoagulant is also associated with an increased risk of developing 
AKI. In contrast, taking an oral anticoagulant was not associated with progression to 
kidney failure.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR 
TRANSLATIONAL SCIENCE?
The risks associated to the use of oral anticoagulant agents might be greater than the 
benefits. The concomitant use of two antithrombotic agents is not recommended in 
patients with CKD especially in the later stages.
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concern.16,23,24 Furthermore, there is a lack of data on the 
putative pharmacodynamic interactions between antiplate-
let agents and oral anticoagulants with regard to the bleed-
ing risk in patients with moderate to advanced CKD.
In addition to the bleeding risk, several studies have re-
ported anticoagulant- induced acute kidney injury (AKI) caused 
by subclinical glomerular hemorrhage.25– 27 It has also been 
suggested that exposure to oral anticoagulants might be asso-
ciated with an accelerated decline in kidney function in these 
patients.28,29
The primary objective of the present study was to assess 
the impact of (i) oral antithrombotics and (ii) the interac-
tions between oral anticoagulants and antiplatelet agents on 
the occurrence of serious adverse events, such as bleeding 
episodes requiring an emergency department visit or hospi-
tal admission, AKI, and CKD progression. The secondary 
objective was, in the subgroup of patients with an indica-
tion for oral anticoagulants, to determine the incidence of 
thromboembolic events and bleeding events as a function of 
whether these drugs were actually prescribed or not.
METHODS
Study design and participants
CKD- REIN is a prospective cohort study carried out in 40 
nationally representative nephrology outpatient facilities in 
France. Details of the study protocol have been published 
elsewhere.30 Briefly, the main inclusion criteria are age 18 
years or over, a confirmed diagnosis of moderate or advanced 
CKD, an estimated glomerular filtration rate (eGFR) less 
than 60 ml/min per 1.73 m2, and the absence of dialysis or 
transplantation. A total of 3033 patients have been included 
in the CKD- REIN study. After the exclusion of 11 patients 
with missing prescription data, the present analysis covered 
3022 patients (Figure 1). The study protocol was approved by 
the institutional review board at the French National Institute 
of Health and Medical Research (INSERM; reference: 
IRB00003888). The study was registered at ClinicalTrials.
gov (NCT03381950).
Information
Trained clinical research associates collected data from pa-
tient interviews and medical records at baseline and then 
annually. The patients’ characteristics (age, sex, smoking 
status, alcohol use, and body mass index) were recorded, 
and the patients were screened for a history of hypertension, 
diabetes, cardiovascular disease, dyslipidemia, or AKI, as 
defined previously.30 Serum levels of creatinine, albumin, 
and hemoglobin, and urine levels of albumin or total pro-
tein were measured. We used the Chronic Kidney Disease 
– Epidemiology Collaboration (CKD- EPI) equation to esti-
mate the GFR.31 Anemia was defined as a blood hemoglobin 
level below 120 g/L for women and below 130 g/L for men. 
Medication Global treatment adherence was evaluated with 
the Girerd score.32
Patients were asked to bring (i) all their drug prescriptions 
from the previous 3 months (regardless of the prescribing 
physician) to their inclusion appointment, and (ii) all pre-
scriptions for the year to each annual follow- up appointment. 
Accordingly, drug prescriptions were continuously recorded 
F I G U R E  1  Study flow chart. CKD- 
REIN, chronic kidney disease study; eGFR, 
estimated glomerular filtration rate
3033 participants in the CKD-REIN cohort
Missing prescription data n=11
3022 included in the analysis
Patients with antithrombotic therapy
n=1535
- Both oral anticoagulant and antiplatelet (n=101)
- Antiplatelet only (n=1095)
- Oral anticoagulant only (n=339)
Patients without antithrombotic at baseline 
n=1487
Patients initiating antithrombotic during follow-up 
n=191
Patients with antithrombotic during 
follow-up
n=1726
Patients without antithrombotic during 
follow-up
n=1296
Patients exposed to antithrombotic 
during follow-up with a baseline 
eGFR≥15 mL/min/1.73m²
N=1660
Patients not exposed to antithrombotic 
during follow-up with a baseline 
eGFR≥15 mL/min/1.73m²
N=1239
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from 3 months preceding inclusion through the end of the fol-
low- up period. A specific electronic medication form linked 
to the international Anatomical Therapeutic Chemical (ATC) 
thesaurus33 was used to code each drug prescription with re-
gard to the brand name, international nonproprietary name, 
ATC class, unit dose, pharmaceutical formulation, admin-
istration route, initiation date, discontinuation date, and (if 
noted in the database) the reason for discontinuation. When 
the exact initiation or discontinuation date was not known, it 
was imputed as the date halfway through the period between 
the previous prescription and the following prescription.
Oral antithrombotic agents encompassed oral anticoagu-
lants (ATC classes B01AA [vitamin K antagonists {VKAs}], 
B01AE [direct thrombin inhibitors], and B01AF [direct 
factor Xa inhibitors]) and antiplatelet agents (B01AC, and 
N02BA01 when the dose level of acetylsalicylic acid was 
below 160 mg).
Atrial fibrillation, valvulopathy, artificial heart valves, 
deep vein thrombosis, and pulmonary embolism at baseline 
were considered as indications for an anticoagulant. Ischemic 
and thromboembolic events (ischemic stroke, transient isch-
emic attack, pulmonary embolism, and deep vein thrombo-
sis) were identified through hospitalization causes.
A modified HAS- BLED score (based on hypertension, 
abnormal renal/liver function, stroke, bleeding history or 
predisposition, elderly age, and drugs/alcohol concomitantly 
but not on the international normalized ratio, which was not 
measured in the present study)34 was computed for patients 
with an indication for anticoagulants.
Study outcomes
The study outcomes were the first bleeding event leading 
to an emergency department visit or hospital admission, the 
first major bleeding event, the first episode of AKI, and pro-
gression to kidney failure.
Bleeding events were identified through hospitalization 
causes, which were coded by a physician according to the 
10th revision of the International Classification of Diseases 
(ICD- 10; Table  S1). A sensitivity analysis (restricted to 
major bleeding events) was performed. A bleeding event 
was considered to be major if the bleeding led to death, oc-
curred in a critical area or organ (i.e., intracranial, intraspinal, 
intra- ocular, retroperitoneal, intra- articular, pericardial, or in-
tramuscular hemorrhages), caused a loss of at least 20 g/L 
of hemoglobin, or required transfusion of at least two red 
blood cell units, as defined by the International Society on 
Thrombosis and Hemostasis (ISTH).35
Episodes of AKI during follow- up were identified and re-
corded (i) by the clinical research associate during the annual 
medical visit, and (ii) by a physician examining all hospital 
reports. All reported episodes of AKI were reviewed by a 
committee of expert nephrologists. The episode was con-
firmed if the serum creatinine value had risen by at least 
50% over a 7- day period or by at least 26 µmol/L over a 48 h 
period (according to the Kidney Disease: Improving Global 
Outcomes [KDIGO] 2012 definition).
Kidney failure (defined as initiation of dialysis or pre- 
emptive transplantation) was identified from medical re-
cords or by linkage with the French National Kidney Failure 
Registry.36 Deaths before kidney failure (concurrent events) 
were identified from medical records or reported by family 
members at the annual follow- up visit.
Statistical analyses
The baseline characteristics were described for the overall 
population (N = 3022) and the subgroups (the presence or 
absence of oral antithrombotic treatment) and reported as the 
median (interquartile range [IQR]) for quantitative variables 
and as the percentage (frequency) for qualitative variables. 
Data from patients with and without prescriptions of oral an-
tithrombotic were compared using Student’s t- test, Fisher’s 
exact test, or the χ2 test.
Incidence rates for each event were computed for periods 
when patients were treated (or not) with oral antithrombot-
ics. We used cause- specific Cox proportional hazard mod-
els to investigate characteristics associated with the risk of 
bleeding, AKI, and progression to kidney failure. Exposure 
to anticoagulant and antiplatelet agents were treated as time- 
dependent covariates. Otherwise, baseline data were used. 
Data were censored on the date of the patient’s third annual 
follow- up visit, the date of last news before the third annual 
follow- up visit, the date of kidney failure, or the date of 
death, whichever occurred first (i.e., for competing events). 
The variables used in the models were selected after a liter-
ature review.37– 39 Variables with a p value greater than 0.10 
in the crude model were excluded from the multivariate anal-
yses. Age and sex were forced into the final model. Patients 
with an eGFR less than 15  ml/min/1.73  m² were excluded 
from the analysis of progression to kidney failure. For all the 
Cox models, the interaction between anticoagulant and an-
tiplatelet variables was tested. If the interaction was statisti-
cally significant, antithrombotic prescriptions were studied in 
four categories: (i) no oral antithrombotics, (ii) an antiplatelet 
agent only, (iii) an oral anticoagulant only, and (iv) an oral 
anticoagulant and an antiplatelet agent. If the interaction was 
not statistically significant, oral anticoagulants and antiplate-
let agents were considered as independent factors in models. 
For all three outcomes, we systematically tested interactions 
with eGFR levels (i.e., <30 or ≥30 ml/min/1.73 m2). Hazard 
ratios (HRs) are presented with their 95% confidence inter-
val (CI). The validity of all models (the proportional hazard 
assumption) was checked by testing the Schoenfeld residuals.
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An exploratory analysis was performed on the subset 
of patients with at least one indication for anticoagulation. 
Incidence rates (95% CI) for ischemic, thromboembolic, and 
bleeding events were calculated for periods when patients 
were being treated (or not) with oral antithrombotics.
To deal with missing data, multiple imputations were 
performed (fully conditional specification method,40 10 data-
sets and 10 iterations) on the patient characteristics from 
Table  1, educational level, serum creatinine level, systolic 
and diastolic blood pressure, baseline heparin level, and 
T A B L E  1  The baseline characteristics of the study population
All patients (n = 3022)




(n = 3022)Yes (n = 1535) No (n = 1487)
Age (years) 69 (60– 76) 72 (66– 79) 64 (53– 72) <0.0001 0%
Men 65.5% 73.3% 57.4% <0.0001 0%
Smoking status <0.0001 1%
Smoker 11.9% 10.0% 13.8%
Nonsmoker 41.3% 34.7% 48.0%
Ex- smoker 46.9% 55.3% 38.2%
Alcohol abuse 1.4% 1.6% 1.2% 0.49 3%
eGFR (ml/min/1.73 m2) 32.9 ± 12.2 32.4 ± 11.6 33.4 ± 12.7 0.03 0%
BMI (kg/m²) 28.7 ± 5.9 29.7 ± 5.7 27.7 ± 5.9 <0.0001 2%
Serum albumin (g/L) 40.2 ± 4.3 40.0 ± 4.2 40.4 ± 4.3 0.01 19%
Proteinuria/creatininuria ratio 0.95 11%
A1: Normal to mildly increased 27.8% 27.7% 28.0%
A2: Moderately increased 31.4% 31.3% 31.6%
A3: Severely increased 40.7% 41.0% 40.4%
Anemia 40.8% 45.6% 35.9% <0.0001 1%
Heart failure 13.0% 21.8% 3.9% <0.0001 0.3%
Coronary heart disease 24.7% 44.2% 4.5% <0.0001 2%
Peripheral arterial disease 13.2% 22.1% 4.1% <0.0001 2%
Stroke history 7.1% 11.6% 2.4% <0.0001 2%
Transient ischemic attack history 3.6% 6.8% 0.3% <0.0001 2%
Cerebral hemorrhage history 0.6% 0.5% 0.6% 0.79 2%
Gastrointestinal bleeding history 4.4% 4.9% 3.8% 0.18 6%
Cirrhosis history 2.2% 2.2% 2.1% 0.78 6%
Hypertension 90.7% 94.7% 86.5% <0.0001 0.1%
Dyslipidemia 73.5% 85.8% 60.8% <0.0001 0.2%
Diabetes 43.0% 56.4% 29.2% <0.0001 0.2%
Acute kidney injury history 23.5% 25.6% 21.3% 0.006 8%
Number of drugs/patients at baseline 8 (5– 10) 9 (7– 12) 6 (4– 8) <0.0001 0%
Treatment adherence <0.0001 1%
Good 37.8% 33.8% 41.9%
Poor 62.2% 66.2% 58.1%
Lipid modifying agents 63.1% 77.2% 48.6% <0.0001 0%
Renin- angiotensin system inhibitors 75.8% 76.7% 75.0% 0.28 0%
Proton pump inhibitors 32.8% 41.2% 24.1% <0.0001 0%
Diuretics 53.1% 65.0% 40.8% <0.0001 0%
Nonsteroidal anti- inflammatory drugs 1.4% 1.1% 1.7% 0.14 0%
Selective serotonin reuptake inhibitors 4.6% 4.5% 4.8% 0.71 0%
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate, based on the Chronic Kidney Disease Epidemiology Collaboration (CKD- EPI) equation.
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prescriptions of antidiabetic agents and allopurinol. The data 
patterns suggested that the assumption whereby data were 
missing at random was plausible. Indicators in Table 1 and 
Cox model regression coefficients were estimated separately 
in each imputed dataset and combined according to Rubin’s 
rules.41 Statistical analyses were performed with SAS soft-
ware (version 9.4; SAS Institute, Cary, NC) and R software 
(version 4.0.2; Foundation for Statistical Computing, Vienna, 
Austria).
RESULTS
Characteristics of the patients and 
antithrombotic agents
Of the 3022 patients, 1535 (51%) had a prescription for one 
or more oral antithrombotic agents at baseline (339 with anti-
coagulants, 1095 with antiplatelet agents, and 101 with both; 
Figure 1, Table 1). On average, patients taking an oral an-
tithrombotic at baseline were significantly older, more likely 
to be men, had more comorbidities, and were taking a greater 
number of drugs at baseline. The baseline eGFR was lower 
in patients taking antithrombotic agents than in patients not 
taking antithrombotic agents.
During a median (IQR) follow- up period of 3.0 (IQR, 
2.8– 3.1) years, 99 (3%) patients not treated at baseline were 
initiated treatment with an oral anticoagulant. Hence, a total 
of 539 (18%) patients received an anticoagulant during the 
follow- up (Figure S2a). Only 49 patients received a direct 
oral anticoagulant (DOAC) during follow- up. Treatment with 
an antiplatelet agent was initiated in 191 patients during the 
follow- up period (Figure S2b).
Bleeding events
During the first 3 years of follow- up, 152 patients had at least 
one bleeding event requiring an emergency department visit 
or a hospital stay, and 24 patients experienced more than 
one bleeding event. One third of the bleeding events were 
gastrointestinal hemorrhages (n = 54), 13% concerned the 
ear- nose- throat area (n = 20), and 7% were cerebral hemor-
rhages (n = 11; Figure  2). More than half of these events 
were major, according to the ISTH definition (n = 79).
The bleeding incidence rate was 1.2 per 100 person- years 
(PYs) for periods when patients were not treated with oral an-
tithrombotics during the follow- up (47 events in 4036 PYs), 
versus 2.6 per 100 PYs for periods when patients were treated 
with oral antithrombotics during the follow- up (105 events in 
3987 PYs; Table S2a).
The interaction between anticoagulants and antiplatelet 
agents was statistically significant (p = 0.02). After multi-
ple adjustments, the risk of bleeding was significantly higher 
for patients treated with an oral anticoagulant only versus 
patients not treated with an oral antithrombotic agent (HR, 
2.38, 95% CI, 1.45– 3.89; Figure 3). This risk was even higher 
when patients had been prescribed both an anticoagulant and 
F I G U R E  2  Description of the bleeding 
events requiring an emergency department 
visit or hospital admission, according to 
type of event and whether or not the event 
was major (n = 152)
F I G U R E  3  Crude and adjusted hazard ratios for bleeding events, 
according to the prescription of oral antithrombotic agents as a time- 
dependent variable in all patients. CI, confidence interval. *Adjusted 
for age, sex, estimated glomerular filtration rate (eGFR; <30 vs. 
≥30 ml/min/1.73 m2), serum albumin, cardiovascular history, diabetes, 
gastrointestinal bleeding history, and number of drugs per patient at 
baseline. Stroke history, cerebral hemorrhage history, alcohol abuse, 
lipid- modifying agent, and selective serotonin reuptake inhibitors were 
tested in a univariate analysis but did not meet the criteria for inclusion 
in the multivariable analysis (p = 0.22, 0.25, 0.44, 0.32, and 0.45, 
respectively). An interaction between antithrombotic treatment and 










Both anticoagulant and antiplatelet
Hazard ratio [95% CI]
0.4 1 2 3 4 5 6 7 13 14
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an antiplatelet agent (HR, 3.96, 95% CI, 2.20– 7.12). The only 
use of antiplatelet therapy was not associated with a higher 
risk of bleeding than for patients without any oral antithrom-
botic. Significant interaction was found with eGFR (HRs oral 
anticoagulant only: 2.62, 95% CI, 1.39– 4.93 and HR, 1.91, 
95% CI, 0.87– 4.20 in patients with eGFR <30 vs ≥30 ml/
min/1.73 m2, and HR anticoagulant + antiplatelet: 5.76, 95% 
CI, 2.85– 11.66 and HR, 1.54, 95% CI, 0.46– 5.12 in patients 
with with eGFR <30 vs. ≥30 ml/min/1.73 m2, interaction p 
= 0.03; Figure S2a).
A sensitivity analysis of major bleeding events gave sim-
ilar results: HR, 3.40, 95% CI, 1.71– 6.76 for anticoagulants 
only; HR, 6.57, 95% CI, 2.99– 14.48 for a combination of 
anticoagulants and antiplatelet agents; HR, 0.66, 95% CI, 
0.32– 1.37 for antiplatelet agents only. Significant interac-
tion was found with eGFR (HRs oral anticoagulant only: 
2.96, 95% CI, 1.27– 6.94 and HR, 3.96, 95% CI, 1.25– 12.55 
in patients with an eGFR <30 vs. ≥30 ml/min/1.73 m2, and 
HR anticoagulant + antiplatelet: HR, 7.53, 95% CI, 2.98– 
18.99 and HR, 4.08, 95% CI, 0.81– 20.44 in patients with an 
eGFR <30 vs. ≥30 ml/min/1.73 m2, interaction p < 0.0001; 
Figure S2b).
Acute kidney injury
Of the 3022 included patients, 414 experienced at least one 
confirmed episode of AKI during the first 3 years of follow-
 up. The AKI incidence rate was 3.2 per 100 PYs for periods 
when patients were not treated with oral antithrombotics (126 
AKIs for 3902 PYs) versus 7.7 per 100 PYs for periods when 
patients received oral antithrombotics (288 AKIs for 3749 
PYs; Table S2a).
After adjustments for confounders, the risk of AKI was 
1.9- fold higher in patients receiving anticoagulants than in 
those not receiving anticoagulant (HR, 1.91, 95% CI, 1.48– 
2.46; Figure  4). No significant interactions were found 
with an eGFR and antiplatelet agents. Antiplatelet ther-
apy was not significantly associated with a higher risk of 
AKI, although a trend could be detected (HR, 1.24, 95% CI, 
0.98– 1.56).
Progression to kidney failure
At baseline, 2899 patients had an eGFR greater than or equal 
to 15 ml/min/1.73 m2; of these, 57% (n = 1660) received an 
oral antithrombotic during the follow- up (Figure 1). During 
the first 3  years of follow- up, 270 patients progressed to 
kidney failure (i.e., dialysis or transplantation). The crude 
incidence rate was 3.4 per 100 PYs. When comparing peri-
ods with and without an oral antithrombotic, the difference 
in the incidence rate was small (3.3 and 3.4 per 100 PYs, 
respectively; Table  S2a). No significant interactions were 
found with eGFR and antiplatelet agents.
Oral antithrombotic agents were not significantly associ-
ated with an increased risk of progression to kidney failure 
(Figure  5). The adjusted HR for patients receiving an oral 
anticoagulant was 1.37, 95% CI, 0.92– 2.04 and the value in 
patients receiving an antiplatelet agent was HR, 1.22, 95% 
CI, 0.89– 1.66.
Exploratory analysis of risks and benefits 
in patients with an indication for an oral 
anticoagulant
Of the 3022 patients included in the CKD- REIN study, 672 
had at least one indication for an oral anticoagulant. Atrial 
fibrillation was the most frequently reported indication 
(Table S3). At baseline, 52% of these patients were actually 
receiving an oral anticoagulant, and around two in five of this 
subset were also receiving an antiplatelet (Table S4). Patients 
receiving an oral anticoagulant were older and were more 
likely to have comorbidities. Patients not treated with an oral 
anticoagulant had a significantly higher HAS- BLED score 
and more antiplatelet prescriptions than those treated with an 
oral anticoagulant (p < 0.0001; Table S4).
During the first 3 years of follow- up, 27 ischemic and 
thromboembolic events were reported (14 ischemic strokes, 
F I G U R E  4  Crude and adjusted hazard ratios for acute kidney 
injury (AKI) events according to prescriptions of oral anticoagulant 
and antiplatelet agents as time- dependent variables in all patients. 
CI, confidence interval. *Adjusted for age, sex, estimated glomerular 
filtration rate (eGRF), serum albumin, anemia, proteinuria/
creatininuria ratio, cardiovascular history, diabetes, history of AKI, 
number of drugs per patient at baseline, treatment adherence, renin- 
angiotensin system inhibitors at baseline, and proton pump inhibitors 
at baseline. Systolic blood pressure and nonsteroidal anti- inflammatory 
drug baseline prescriptions were tested in a univariate analysis but 
did not meet the criteria for inclusion in the multivariable analysis 
(p = 0.18 and p = 0.22, respectively). The interaction between oral 
anticoagulant and antiplatelet was not statistically significant (p = 
0.20), as well as the interaction between oral anticoagulant and eGFR 
(p = 0.30)
Crude analysis
With anticoagulants vs without
With antiplatelet agents vs without
Adjusted model*
With anticoagulants vs without
With antiplatelet agents vs without
Hazard ratio [95% CI]
0.5 1 1.2 1.5 1.9 2.5 3
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3 transient ischemic attacks, and 10 cases of deep vein throm-
bosis or pulmonary embolism). The crude incidence rate 
was 1.6 per 100 PYs (27 events for 1718 PYs). This crude 
incidence rate was two times greater for periods when pa-
tients were not treated with an oral anticoagulant than for 
periods when patients were receiving an oral anticoagulant 
(Table S2b). The small number of events prevented us from 
performing a multivariable analysis.
During the same period, 70 bleeding events requiring an 
emergency department visit or hospital admission were re-
ported in the subset of patients with an indication for an oral 
anticoagulant. Findings for bleeding events in this subgroup 
were consistent with those in the overall population (HR oral 
anticoagulant vs. no anticoagulant, 3.13, 95% CI, 1.74– 5.64, 
but the interaction between antiplatelet and oral anticoagu-
lant was not statistically significant (Tables S2b and S5).
DISCUSSION
In a large cohort of French patients with CKD, we found that 
almost a quarter of those treated with oral anticoagulants 
were also receiving antiplatelet drugs. The risk of bleeding 
in patients with CKD receiving an oral anticoagulant only 
was almost 2.5 times higher than in untreated patients and 
was four times higher when an oral anticoagulant and an an-
tiplatelet agent were used concomitantly. The present large 
prospective CKD cohort study is the first of its kind, by its 
large number of included participants, to show that taking an 
oral anticoagulant is also associated with an increased risk of 
developing AKI. In contrast, taking an oral anticoagulant was 
not associated with progression to kidney failure.
In line with the observed prevalence of cardiovascular 
comorbidities, respectively, 15% and 40% of the study par-
ticipants were being treated with oral anticoagulants and 
antiplatelet agents at baseline. It is noteworthy that when 
considering oral anticoagulants, VKAs were frequently used 
and prescriptions of DOACs were very rare. The pharmaco-
kinetics and bioavailability of anticoagulants are altered in 
patients with CKD.42 Furthermore, DOACs (but not VKAs) 
are mainly excreted by the kidneys.43 The exclusion of pa-
tients with a creatinine clearance rate below 30 ml/min from 
clinical trials of DOAC and the need for DOAC dose adjust-
ments according to the level of kidney function might lead 
to underprescription in these patients (relative to non- CKD 
populations).
Here, we focused on the risks associated with the use of 
oral antithrombotic drugs and, in particular, on the bleeding 
risk. In the present cohort, the bleeding risk was four times 
higher in patients receiving both oral anticoagulants and an-
tiplatelet agents than in patients not receiving any antithrom-
botic agents; this finding highlights a pharmacodynamic 
interaction between the two drug classes. Our results are 
in line with a Danish national registry study,16 in which the 
risk of bleeding was significantly higher in patients taking 
warfarin (alone or combined with aspirin) than in nontreated 
patients. However, the Danish study was retrospective, and 
CKD stage data were not reported. Other studies in popula-
tions of predialysis patients with CKD reported that an an-
tithrombotic use is associated with a nonsignificant risk of 
bleeding.17,18,20 Of note, we found a higher risk of bleeding 
and major bleeding in patients with eGFR less than 30 ml/
min/1.73 m2. In the same line, Limdi et al. found that com-
pared to patients with eGFR greater than or equal to 60 ml/
min/1.73 m2, those with eGFR 30– 44 ml/min/1.73 m² are at a 
twofold higher risk of hemorrhage and those with eGFR less 
than 30 ml/min/1.73 m² are at a 5.6- fold higher risk.44 Our re-
sults are consistent with the findings in patients receiving he-
modialysis,45 in whom the prescription of oral anticoagulants 
is subject to debate46; some researchers have even suggested 
that these drugs should not be used in dialyzed patients be-
cause of their poor benefit/risk ratio.47
Our study is the first to show that taking an oral antico-
agulant is associated with an increased risk of AKI in a large 
CKD cohort. Indeed, tubular nephropathies have recently 
been linked to use of the oral anticoagulants warfarin, flu-
indione, and dabigatran.25 Patients with CKD are at greater 
risk of excessive anticoagulation, due to the negative impact 
of poor renal function on the clearance and metabolism of 
oral anticoagulants.43,44 Excessive anticoagulation can lead 
to AKI resulting from glomerular bleeding and tubular ob-
struction caused by an accumulation of red blood cells.26 
F I G U R E  5  Crude and adjusted hazard ratios for kidney failure 
events according to prescriptions of oral anticoagulant and antiplatelet 
agents as time- dependent variables in patients with a baseline 
estimated glomerular filtration rate (eGFR) greater than or equal 
to 15 ml/min/1.73 m2. CI, confidence interval. *Adjusted for age, 
sex, eGFR, body mass index, serum albumin, anemia, proteinuria/
creatininuria ratio, systolic blood pressure, cardiovascular history, 
diabetes, history of acute kidney injury, number of drugs per patient at 
baseline, treatment adherence, renin- angiotensin system inhibitors at 
baseline, diuretics at baseline, and proton pump inhibitors at baseline. 
The interaction between oral anticoagulant and antiplatelet was not 
statistically significant (p = 0.51), as well as the interaction between 
oral anticoagulant and eGFR (p = 0.30)
Crude analysis
With anticoagulants vs without
With antiplatelet agents vs without
Adjusted model*
With anticoagulants vs without
With antiplatelet agents vs without
Hazard ratio [95% CI]
0.5 1 1.2 1.4 2 2.5
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The diagnosis of anticoagulant- related nephropathy is based 
on a renal biopsy— an invasive test rarely performed in pa-
tients taking an anticoagulant. CKD is a risk factor for AKI 
and (probably) anticoagulant- related nephropathy.26 Few 
studies have evaluated the association between taking oral 
anticoagulants and the occurrence of AKI in patients with 
moderate- to- severe CKD.48,49 Most of the few available 
studies compared DOACs with VKAs.50,51 Although the in-
cidence of anticoagulant- related nephropathies is probably 
underestimated, the observation of marked hematuria before 
AKI should prompt the physician to consider this diagnosis.
Our analysis did not show an association between oral 
anticoagulant use and progression to kidney failure. Some 
researchers have hypothesized that anticoagulant use is asso-
ciated with the progression of CKD. Individuals with CKD 
taking oral anticoagulants may experience repeated episodes 
of poorly identified clinical or subclinical glomerular bleed-
ing, which could accelerate the fall over time in the eGFR. 
Furthermore, it is known that VKAs prevent gamma car-
boxylation of the matrix Gla protein (an inhibitor of vascu-
lar calcification) and thus hasten the appearance of arterial 
calcification.52 In turn, arterial calcification might contribute 
to the progression of CKD. However, the literature data di-
verge with regard to the risk of CKD progression and the 
use of anticoagulants in patients with moderate- to- advanced 
CKD.29,53 A large, retrospective study that included patients 
with stage three and four CKD, showed that disease progres-
sion (based on a change in eGFR over a median follow- up 
period of 1.5 years) was faster in patients treated with VKAs 
than in those who were not.29 Although the assessment cri-
teria were different, these results disagree with our present 
findings. In a 2- year study of 984 patients with CKD (eGFR: 
between 20 and 30 ml/min/1.73 m2), VKA use was not as-
sociated with an accelerated decline in renal function or an 
earlier onset of dialysis.53
When choosing a treatment, the physician must take ac-
count of both risks and benefits. As shown here, the risks 
associated with oral anticoagulant treatment of patients with 
CKD appear to be elevated— especially for VKAs and anti-
platelet agents. Only a few studies have sought to assess the 
benefit of oral anticoagulant treatment in the CKD popula-
tion. Carrero et al. found a benefit of anticoagulants in predi-
alysis patients with CKD after a myocardial infarction; there 
was a significant reduction in the risk of ischemic stroke.20 
In contrast, several studies have not found any significant 
benefits of anticoagulants in predialysis patients, although 
a general trend toward benefit was observed.16– 19,23 Among 
patients with an indication for oral anticoagulation in the 
CKD- REIN study, our exploratory analysis showed a non-
significant protective trend (i.e., toward a reduction in the 
risk of thromboembolic events). However, the small num-
ber of events prevented us from adjusting this analysis. We 
also evaluated bleeding in the same subset; the risk was three 
times higher among patients actually treated with oral anti-
coagulants than in nontreated patients. One can therefore le-
gitimately question the balance between the decrease risk of 
thromboembolic events and the increased risk of bleeding as-
sociated with antithrombotics (and especially oral anticoag-
ulants), in this particular population. Furthermore, bleeding 
was not the only harmful event associated with oral antico-
agulant prescription. When treating patients with CKD, it is 
important to evaluate other options (such as DOACs) with 
potentially high levels of efficacy and safety in the setting 
of kidney disease; this can only be confirmed by meticulous, 
prospective clinical investigation.
For patients with CKD with atrial fibrillation, the value 
of percutaneous left atrial appendage occlusion (to exclude 
the most prevalent source of thrombus formation) can be 
questioned because few studies have evaluated this method 
(reserved for patients with a high bleeding risk on oral an-
ticoagulants) in the context of CKD.54,55 Last, the benefit of 
concomitant use of oral anticoagulants and antiplatelet agents 
needs to be carefully assessed, given the major known risk.
The main strengths of this study lie in its prospective de-
sign and its large, well- characterized sample of patients with 
CKD. The longitudinally drug records (with start and stop 
dates) enabled us to take account of oral antithrombotic treat-
ments as time- dependent covariates. Our analyses were not 
limited to one particular oral antithrombotic agent. Another 
strength relates to the fact that the sensitive, specific iden-
tification of events by experts greatly reduced the misclas-
sification of the study outcomes. Last, comparison of the 
CKD- REIN database with the French national kidney failure 
registry enabled us to precisely identify kidney failure events.
Our study had some limitations. First, due to the low 
number of patients with DOAC prescriptions, we could 
not compare VKAs and DOACs. Second, our results were 
limited to the first event, which potentially skewed the 
exposure- event association. However, few patients pre-
sented repeated events during the first 3 years of follow- up. 
Third, we may not have captured all hospital admissions 
and in- hospital events. Given the low number of incident 
thromboembolic events during the first 3 years of the study, 
our analysis of the benefit of anticoagulants in patients with 
an indication for oral anticoagulation could only be carried 
out on an exploratory basis (i.e., as a crude analysis); a 
longer follow- up might have allowed us to perform an ad-
justed analysis. Finally, residual confounding is a further 
limitation, given that a number of unknown or unmeasured 
risk factors may have not been included in the analyses 
and might explain the observed associations. Confounding 
by indication could potentially overestimate the true risk. 
Finally, although prevalent user bias is a common bias en-
countered in pharmacoepidemiology studies, it mostly con-
cerns drug efficacy evaluation. The inclusion of prevalent 
users may lead to an underestimation of the adverse effects 
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that occur at the beginning of treatment. Thus, we cannot 
rule out a possible underestimation of the risk.
In conclusion, treatment with oral antithrombotics should 
be initiated with caution in patients with CKD, and the bene-
fit/risk ratio should be reassessed on a regular basis. Our re-
sults confirm the high risk of bleeding in patients with CKD 
treated with antithrombotics, and highlighted a notable in-
teraction between oral anticoagulants and antiplatelet agents. 
The risk of AKI linked to oral anticoagulant prescriptions in 
patients with CKD warrants further investigation. The value 
of oral anticoagulant therapy in preventing the thromboem-
bolic complications of atrial fibrillation in CKD can only be 
established in a randomized, controlled clinical trial.
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